Tags Archive Navigation
icon
-
Media ReleaseNovartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
-
Media ReleaseNew Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patients
-
Media ReleaseFDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
-
StoryIs Diversity, Equity and Inclusion (DEI) really that important?
-
Media ReleaseNovartis Scemblix® granted FDA Priority Review for the treatment of adults with newly diagnosed CML
-
Media ReleaseNovartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehoben
-
Media ReleaseNovartis a poursuivi au T2 la forte croissance de son chiffre d’affaires et l’expansion de sa marge core; hausse des prévisions de son résultat opérationnel core pour 2024
-
Media ReleaseNovartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance
-
Media ReleaseNovartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
-
Media ReleaseNovartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
-
Media ReleaseNovartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
-
StoryFrom black holes to AI driven drug discovery – collaboration wins the day
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 17
- › Next page